A Study of GFH009 in Patients With Hematologic Malignancies
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
GFH009 is a potent and highly selective CDK9 inhibitor. The study consists of a dose
escalation and a dose expansion part. The purpose of this study is to investigate the safety
and tolerability of GFH009 in relapsed/refractory hematologic malignancies [acute myeloid
leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and
lymphoma], will also explore the preliminary anti-tumor activities of GFH009 in the studied
population.